Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

Inclusion Criteria: * Clinical diagnosis of HIV Disease * Age \> 18 years old * Receiving a stable ARV regimen for at least the last 12 weeks prior to study entry and cumulative duration of ARV for 12 months * Fasting LDL cholesterol \< 130 mg/dl * Fasting triglycerides \< 300 mg/dL * hsCRP \> 2 mg/L or CD38+DR+/CD8+ \> 19% * If on Vit D replacement therapy, stable regimen for \> 3 months prior to study entry Exclusion Criteria: * Women who are pregnant or breast feeding * Any active or chronic inflammatory condition * Cardiovascular disease * Current or recent (within 24 weeks of study entry) therapy with omega-3 fatty acids, fibrates, ezetimibe or statins * Uncontrolled hypothyroidism or hyperthyroidism * Uncontrolled diabetes * Use of systemic cancer chemotherapy of immunomodulating agents * Use of Anabolic agents, growth hormone, growth hormone releasing factor, or any other anabolic agents, except for stable replacement testosterone. * Use of biphosphonates or other bone therapies * Any of the following lab findings obtained within 14 days prior to the screening evaluation including the following: * AST and/or ALT \> 2.5 x ULN * Hemoglobin \< 9.0 g/dL * CK \> 3 X ULN * Calculated creatinine clearance \< 50 mL/min